Bristol Myers Squibb Company $BMY Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama raised its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,408,599 shares of the biopharmaceutical company’s stock after purchasing an additional 106,893 shares during the period. Retirement Systems of Alabama’s holdings in Bristol Myers Squibb were worth $75,980,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter worth about $35,000. JPL Wealth Management LLC bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at about $36,000. Finally, Total Investment Management Inc. acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at about $38,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $59.76 on Tuesday. The business has a 50 day moving average price of $58.91 and a two-hundred day moving average price of $52.35. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a market capitalization of $122.01 billion, a price-to-earnings ratio of 17.32, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm posted $1.67 EPS. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Morgan Stanley reissued an “underweight” rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a report on Friday, February 6th. HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Finally, Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.41.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase 3 SCOUT‑HCM data for Camzyos (mavacamten) in adolescents showed efficacy and safety, increasing the drug’s addressable market and raising the chance of label expansion and incremental sales for BMY’s cardiovascular franchise. Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT‑HCM Trial
• Positive Sentiment: The FDA granted approval for BMY’s combination regimen in Hodgkin’s lymphoma (announced March 20), adding a near‑term revenue stream and supporting sentiment around the oncology portfolio. Bristol‑Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Neutral Sentiment: Phase 4 data for Cobenfy (xanomeline+tropium) presented safety/tolerability data in switching patients, which could reshape long‑term revenue assumptions if follow‑on studies or real‑world switching data are favorable — outcome still uncertain for valuation impact. Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Analyses highlight growth opportunities in the pancreatic adenocarcinoma market (projected high CAGR) where BMY is named among major players — long‑term tailwind but competitive landscape and timing of launches matter. Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR
• Neutral Sentiment: Several financial writeups point to BMY as an income/dividend name and note an upcoming ex‑dividend date; that can support demand from yield‑focused investors but doesn’t change fundamentals. Bristol‑Myers Squibb Looks Like A Good Stock, And It’s Going Ex‑Dividend Soon
• Negative Sentiment: Analyst coverage is mixed — roughly 60% of covering analysts have non‑bullish ratings even though the consensus price target implies limited upside, which could cap upside until guidance or earnings beat expectations and analysts raise targets. Bristol‑Myers Squibb Faces Mixed Analyst Sentiment

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.